JAMIE BELGARD: Open Payments
NPI 1396186482 · ALEXANDRIA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$882 in 31 payments from 10 companies in 2025. Trend: 2023 $973 · 2024 $1,039 · 2025 $882
Food & beverage: $882
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 3 | $259 |
| ABBVIE INC. | 11 | $155 |
| Janssen Pharmaceuticals, Inc | 1 | $124 |
| Otsuka America Pharmaceutical, Inc. | 5 | $103 |
| Neurocrine BioSciences, Inc. | 4 | $95 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $55 |
| Alkermes, Inc. | 2 | $34 |
| Lundbeck LLC | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| Braeburn Inc. | 1 | $19 |
Products named: Auvelity, VRAYLAR, INVEGA SUSTENNA, REXULTI, INGREZZA, CAPLYTA, ABILIFY ASIMTUFII, ARISTADA.
Industry payments across LA — which companies pay providers there.
